2015 American Society of Hematology Annual Meeting*

December 5-8, 2015; Orlando, Florida
This program provides coverage of the 2015 ASH annual meeting with PowerPoint summaries and expert analysis of the most clinically relevant study results with downloadable highlights slidesets. Topics include leukemias, lymphomas, myelodysplastic syndromes or myeloproliferative neoplasms, and multiple myeloma or other plasma cell disorders.
John M. Burke, MD
Elias Jabbour, MD
Brad S. Kahl, MD
Rami S. Komrokji, MD
Shaji Kumar, MD
person default
Sagar Lonial, MD
Farhad Ravandi, MD
Jamile Shammo, MD, FASCP, FACP

Acute and Chronic Leukemias

Results of a phase III trial investigating the addition of rituximab to chemotherapy in B-cell ALL.

Released: December 8, 2015

Addition of clofarabine to cytarabine consolidation therapy showed significantly improved DFS in patients with higher-risk AML without SCT.

Released: December 9, 2015

In this phase III study, addition of ATO allowed anthracycline dose to be reduced; event-free survival improved over historic controls.

Released: December 8, 2015

Combining venetoclax with azacitidine or decitabine as initial therapy was tolerable and active in elderly patients with AML.

Released: December 10, 2015

Results from this phase III trial suggest that addition of ATO to frontline chemotherapy may further reduce relapse rates in APL.

Released: December 11, 2015

Early data suggest potential clinical benefit from this combination.

Released: December 15, 2015

In this phase III trial, radotinib associated with higher molecular response and lower treatment failure vs imatinib.

Released: December 11, 2015

Retrospective observational data indicated that ponatinib achieved significantly longer OS in T315I+ CP-CML vs alloSCT.

Released: December 12, 2015

Midostaurin added to chemotherapy significantly improved survival vs placebo in patients with FLT3-mutated AML.

Released: December 11, 2015

Early data suggest that blinatumomab monotherapy has antileukemic activity in Ph+ B-precursor ALL after failure on TKI therapy.

Released: December 10, 2015

Patients with complete MRD response after blinatumomab treatment had prolonged OS, RFS, and DoR vs those with an incomplete MRD response.

Released: December 14, 2015

Potent and durable antitumor activity seen in pediatric patients with relapsed/refractory ALL.

Released: December 13, 2015

MRD-negative CR following 19-28z CAR T-cell infusion associated with superior OS.

Released: December 18, 2015

Addition of targeted therapy to chemotherapy increased efficacy with low rate of severe AEs.

Released: December 7, 2015

In a subanalysis of a phase II trial, patients with R/R B-precursor ALL after alloHSCT achieved a 45% CR/CRh rate with blinatumomab treatment.

Released: December 14, 2015

In this Expert Analysis, Elias Jabbour, MD, and Farhad Ravandi, MD, review and discuss the clinical relevance of key studies in acute and chronic leukemias presented at the 2015 ASH annual meeting.

Elias Jabbour, MD Farhad Ravandi, MD Physicians: maximum of 2.5 AMA PRA Category 1 Credits Released: February 26, 2016 Expiration: February 25, 2017

Elias Jabbour, MD, and Farhad Ravandi, MD, review key studies and data presented at the 2015 American Society of Hematology Annual Meeting relevant to the management of patients with acute leukemias and chronic leukemias.

Released: January 11, 2016

Lymphomas

DA-EPOCH-R highly active in Burkitt lymphoma with reduced toxicity vs high-intensity treatment regimens.

Released: December 11, 2015

Fewer AEs and significantly longer PFS and ORR with ibrutinib vs temsirolimus.

Released: December 9, 2015

Phase II data suggest that the chemotherapy-free regimen of ibrutinib plus rituximab is highly active in treatment-naive FL.

Released: December 10, 2015

Ibrutinib is active in primary CNS lymphoma, achieving clinically meaningful CSF concentrations.

Released: December 8, 2015

In this phase III trial that enrolled elderly treatment-naive patients with CLL, ibrutinib was associated with significant reductions in risk of progression and death vs chlorambucil.

Released: December 12, 2015

In this phase II trial, R-bendamustine induction showed similar response rates, 2-year PFS, and 2-year OS with less hematologic and marrow toxicity vs R-hyperCVAD.

Released: December 11, 2015

Use of interim PET allows more patients to avoid IFRT while still achieving 3-year PFS.

Released: December 12, 2015

Phase I/II data suggest promise of combining brentuximab vedotin with ESHAP for patients with relapsed/refractory cHL who are transplantation candidates.

Released: December 15, 2015

In this early study, pembrolizumab was highly active with durable responses in heavily pretreated patients with cHL who had failed brentuximab vedotin.

Released: December 14, 2015

Alternate kinase inhibitor therapy following ibrutinib or idelalisib discontinuation can be efficacious.

Released: December 12, 2015

Addition of 2 doses of bortezomib to frontline R-CHOP resulted in similar 2-year PFS rates in non-GCB DLBCL defined by the Hans IHC method.

Released: December 12, 2015

Preliminary data show promising activity for the combination of venetoclax and rituximab, including an ORR of 86% and durable responses in the 55% of patients who achieved MRD negativity.

Released: December 16, 2015

In this early-stage study, ACP-196 demonstrated promising activity in high-risk R/R CLL regardless of the presence of del(17p).

Released: December 15, 2015

In this expert analysis, John M. Burke, MD, and Brad S. Kahl, MD, discuss the most clinically relevant data on the management of lymphomas presented at the 2015 American Society of Hematology annual meeting.

John M. Burke, MD Brad S. Kahl, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 17, 2016 Expiration: February 16, 2017

Combination idelalisib plus BR therapy significantly improved survival outcomes in patients with R/R CLL.

Released: December 17, 2015

Single-agent venetoclax is active and achieved deep responses in relapsed/refractory CLL with del(17p).

Released: December 14, 2015

In this downloadable slideset, John M. Burke, MD, and Brad S. Kahl, MD, review data from key studies in lymphoma presented at the 2015 American Society of Hematology Annual Meeting.

Released: January 25, 2016

Myelodysplastic syndrome and myeloproliferative neoplasms

Promising early-phase results suggest potential benefit to telomerase inhibition in RARS/RARS-T.

Released: December 9, 2015

PRM-151 was well tolerated with observed reductions in bone marrow fibrosis and symptom scores, as well as improved anemia, thrombocytopenia.

Released: December 8, 2015

Benefits from pacritinib observed regardless of baseline characteristics, including platelet count.

Released: December 10, 2015

Durable efficacy with reductions in bone marrow fibrosis, JAK2 V617F allele burden, and risk of death sustained over longer-term use of ruxolitinib.

Released: December 9, 2015

PegIFN2a is effective treatment for ET/PV as shown by favorable long-term hematologic and molecular responses.

Released: December 10, 2015

Reduced splenomegaly observed with the combination, and patients with JAK2 mutations achieved higher response rates vs those without.

Released: December 12, 2015

Ruxolitinib addition to IFN-α2 showed early activity with a manageable toxicity profile in tx-experienced MPN.

Released: December 10, 2015

Combination therapy was well tolerated and showed preliminary efficacy similar to single-agent ruxolitinib.

Released: December 10, 2015

A combination of ruxolitinib + pomalidomide showed reduction of splenomegaly and improvement of cytopenia in some patients with pretreated and high-risk MF.

Released: December 12, 2015

SF3B1 mutations demonstrated favorable prognostic significance in multivariable survival model of MDS and several additional mutations were associated with adverse prognosis.

Released: December 13, 2015

Phase II data suggest that eltrombopag is effective with a toxicity profile similar to placebo.

Released: December 7, 2015

Data from this small study suggest rigosertib plus azacitidine therapy may be effective and safe in this setting.

Released: December 14, 2015

Randomized, placebo-controlled phase II trial evaluated this novel combination in patients with previously untreated MDS.

Released: December 15, 2015

Improvement in anemia and reduced transfusion burden sustained for up to 1 year.

Released: December 8, 2015

Overall response rate 59% among patients with lower-risk MDS treated with low-dose azacitidine or decitabine.

Released: December 11, 2015

In this expert analysis, Jamile Shammo, MD, FASCP, FACP, and Rami S. Komrokji, MD, discuss the clinical relevance of key findings in myelodysplastic syndromes and myeloproliferative neoplasms presented at the 2015 American Society of Hematology Annual Meeting.

Rami S. Komrokji, MD Jamile Shammo, MD, FASCP, FACP Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: February 24, 2016 Expiration: February 23, 2017

In this downloadable slideset, Rami S. Komrokji, MD, and Jamile Shammo, MD, FASCP, FACP, review data from key studies in myelodysplastic syndrome and myeloproliferative neoplasms presented at the 2015 American Society of Hematology Annual Meeting.

Released: January 11, 2016

Multiple myeloma and other plasma cell disorders

MRD negativity at 10-6 level (using next generation sequencing) strongly predicts PFS.

Released: December 12, 2015

Addition of bortezomib to lenalidomide plus dexamethasone induction significantly improves survival in patients with newly diagnosed MM without plans for immediate ASCT.

Released: December 7, 2015

First all-oral proteasome inhibitor–based combination showed promising efficacy and manageable toxicity in untreated MM.

Released: December 8, 2015

Long-term bortezomib-based therapy improves survival, including patients with del(17p) or renal impairment.

Released: December 7, 2015

At the 3-year follow-up, addition of elotuzumab to lenalidomide/dexamethasone reduced risk of disease progression or death by 27%.

Released: December 7, 2015

Weekly carfilzomib/dexamethasone is active with similar or lower toxicity than historical data with standard twice-weekly dosing.

Released: December 9, 2015

Results from IFM 2009, which addressed the role of ASCT in the era of effective triplet combination therapy, showed improved PFS and suggest that ASCT in newly diagnosed myeloma should remain a standard of care.

Released: December 10, 2015

VTD showed superior rates of ≥ VGPR vs VCD as induction therapy. Treatment with VCD resulted in higher rates of hematologic toxicity, whereas VTD resulted in more peripheral neuropathy.

Released: December 9, 2015

PET/CT after 3 cycles of systemic therapy and before maintenance predictive of efficacy endpoints in younger patients receiving RVD.

Released: December 11, 2015

Early results with pembrolizumab plus lenalidomide/dexamethasone show promising efficacy and acceptable safety profile in a heavily pretreated population of R/R MM.

Released: December 10, 2015

Early results show promising efficacy and acceptable safety profile in a heavily pretreated population.

Released: December 11, 2015

In this early analysis, combining daratumumab with pomalidomide/dexamethasone showed promising responses in heavily pretreated patients and was tolerable.

Released: December 12, 2015

Newly FDA approved ixazomib combination therapy with lenalidomide/dexamethasone prolongs PFS and increases response rate in patients with R/R MM.

Released: December 11, 2015

Carfilzomib plus filanesib vs single-agent carfilzomib associated with longer median PFS for patients with pretreated R/R MM.

Released: December 10, 2015

In this activity, Shaji Kumar, MD, and Sagar Lonial, MD, discuss the clinical impact of emerging data presented at the 2015 ASH annual meeting on the treatment of patients with newly diagnosed or relapsed/refractory multiple myeloma.

Shaji Kumar, MD person default Sagar Lonial, MD Physicians: maximum of 1.75 AMA PRA Category 1 Credits Released: March 3, 2016 Expiration: March 2, 2017

Early study suggests activity of CAR-BCMA T cells in myeloma.

Released: December 16, 2015

In this downloadable slideset, Shaji Kumar, MD, and Sagar Lonial, MD, review data from key studies in multiple myeloma presented at the 2015 American Society of Hematology Annual Meeting.

Released: January 19, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics
Takeda Oncology

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?